Trial · NCT01970865
Adverse events9,792
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 9,792
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | 10 mg QD (Phase 1) | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | 25 mg QD (Phase 1) | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | 50 mg QD (Phase 1) | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | 75 mg QD (Phase 1) | 3 | 12 | |
| other | Anaemia | Blood and lymphatic system disorders | 100 mg QD (Phase 1) | 7 | 17 | |
| other | Anaemia | Blood and lymphatic system disorders | 150 mg QD (Phase 1) | 3 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | 200 mg QD (Phase 1) | 1 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | 35 mg BID (Phase 1) | 1 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | 75 mg BID (Phase 1) | 2 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | 100 mg BID (Phase 1) | 2 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Japan Lead-In Cohort (LIC) | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | EXP-1 (Phase 2) | 6 | 30 | |
| other | Anaemia | Blood and lymphatic system disorders | EXP-2 (Phase 2) | 2 | 27 | |
| other | Anaemia | Blood and lymphatic system disorders | EXP-3 (Phase 2) | 6 | 60 | |
| other | Anaemia | Blood and lymphatic system disorders | EXP-4 (Phase 2) | 18 | 65 | |
| other | Anaemia | Blood and lymphatic system disorders | EXP-5 (Phase 2) | 7 | 46 | |
| other | Anaemia | Blood and lymphatic system disorders | EXP-6 (Phase 2) | 7 | 47 | |
| other | Anaemia | Blood and lymphatic system disorders | DDI Substudy | 8 | 32 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | 10 mg QD (Phase 1) | 0 | 3 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | 25 mg QD (Phase 1) | 0 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01970865/events